Chorioallantoic membrane assay demonstrating pro-angiogenic properties of BRAF inhibitor: a tool to treat chronic wounds

The aim of the study was to evaluate the angiogenic potential and safety of Dabrafenib, a BRAF inhibitor, for wound healing applications using the chick embryo Chorioallantoic Membrane (CAM) assay. Fertilized chicken eggs were incubated, and CAM assay was performed to assess angiogenesis. The number of blood vessels was quantified using Image J software. An irritation test was conducted by applying Dabrafenib to the CAM and observing vascular changes. Additionally, the effects of dabrafenib on the secretion of Vascular Endothelial Growth Factor (VEGF-A) and Fibroblast Growth Factor 2 (FGF2) in HaCaT cell lines were investigated. Dabrafenib demonstrated a dose-dependent pro-angiogenic effect, with a EC50 of 1.196 mM. The irritation test indicated no significant irritation with Dabrafenib. There was a 4.2-fold and 5.6-fold increase from control in the VEGF-A and FGF2 groups, respectively. Dabrafenib demonstrated angiogenic potential and was nonirritating, indicating its safety for topical application.